PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 103 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2021. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,921,393 | -25.3% | 3,772,393 | +0.2% | 0.00% | – |
Q2 2023 | $13,287,383 | +14.0% | 3,764,131 | -0.2% | 0.00% | – |
Q1 2023 | $11,653,456 | -23.2% | 3,771,345 | +5.1% | 0.00% | – |
Q4 2022 | $15,181,140 | +76.8% | 3,588,922 | -1.0% | 0.00% | – |
Q3 2022 | $8,588,000 | -17.0% | 3,623,629 | -0.2% | 0.00% | – |
Q2 2022 | $10,349,000 | +3.6% | 3,631,429 | +4.7% | 0.00% | – |
Q1 2022 | $9,985,000 | -10.8% | 3,466,840 | -5.8% | 0.00% | – |
Q4 2021 | $11,188,000 | -56.0% | 3,680,187 | +1.4% | 0.00% | -100.0% |
Q3 2021 | $25,442,000 | -22.7% | 3,629,433 | +1.2% | 0.00% | 0.0% |
Q2 2021 | $32,920,000 | -4.3% | 3,586,043 | +1.3% | 0.00% | 0.0% |
Q1 2021 | $34,394,000 | -1.3% | 3,538,455 | +4.2% | 0.00% | 0.0% |
Q4 2020 | $34,851,000 | -0.6% | 3,396,689 | -2.2% | 0.00% | 0.0% |
Q3 2020 | $35,050,000 | -22.3% | 3,473,796 | -19.7% | 0.00% | -50.0% |
Q2 2020 | $45,119,000 | +15.3% | 4,325,988 | -6.7% | 0.00% | 0.0% |
Q1 2020 | $39,117,000 | +12.2% | 4,634,697 | +16.3% | 0.00% | +100.0% |
Q4 2019 | $34,878,000 | -7.3% | 3,986,126 | +14.0% | 0.00% | 0.0% |
Q3 2019 | $37,631,000 | -3.4% | 3,495,704 | +14.0% | 0.00% | 0.0% |
Q2 2019 | $38,964,000 | -65.9% | 3,065,679 | +4.0% | 0.00% | -75.0% |
Q1 2019 | $114,311,000 | +101.0% | 2,946,894 | +5.4% | 0.00% | +33.3% |
Q4 2018 | $56,873,000 | -56.0% | 2,794,737 | -0.9% | 0.00% | -40.0% |
Q3 2018 | $129,257,000 | -20.1% | 2,819,118 | +3.1% | 0.01% | -28.6% |
Q2 2018 | $161,704,000 | -10.3% | 2,733,799 | +3.2% | 0.01% | -12.5% |
Q1 2018 | $180,318,000 | -30.2% | 2,649,799 | +1.3% | 0.01% | -27.3% |
Q4 2017 | $258,500,000 | -15.3% | 2,615,069 | +2.6% | 0.01% | -21.4% |
Q3 2017 | $305,270,000 | +41.1% | 2,549,228 | +3.0% | 0.01% | +27.3% |
Q2 2017 | $216,284,000 | +139.4% | 2,474,644 | +1.9% | 0.01% | +120.0% |
Q1 2017 | $90,355,000 | +26.5% | 2,428,909 | +4.4% | 0.01% | +25.0% |
Q4 2016 | $71,445,000 | -46.8% | 2,327,187 | +16.1% | 0.00% | -50.0% |
Q3 2016 | $134,368,000 | +133.8% | 2,003,986 | +3.9% | 0.01% | +100.0% |
Q2 2016 | $57,477,000 | +6.7% | 1,929,407 | +5.2% | 0.00% | +33.3% |
Q1 2016 | $53,860,000 | -61.6% | 1,833,837 | +2.5% | 0.00% | -66.7% |
Q4 2015 | $140,265,000 | +4.9% | 1,789,112 | +0.8% | 0.01% | +80.0% |
Q3 2015 | $133,762,000 | -34.5% | 1,774,973 | +1.4% | 0.01% | -64.3% |
Q2 2015 | $204,317,000 | -47.9% | 1,750,041 | +5.4% | 0.01% | -48.1% |
Q1 2015 | $391,847,000 | +35.9% | 1,659,598 | +9.0% | 0.03% | +28.6% |
Q4 2014 | $288,280,000 | -19.5% | 1,523,115 | +1.5% | 0.02% | -25.0% |
Q3 2014 | $358,146,000 | +263.7% | 1,501,216 | +0.6% | 0.03% | +250.0% |
Q2 2014 | $98,483,000 | -36.6% | 1,492,173 | +0.1% | 0.01% | -38.5% |
Q1 2014 | $155,241,000 | +13.0% | 1,490,694 | +12.3% | 0.01% | +8.3% |
Q4 2013 | $137,388,000 | +108.6% | 1,327,038 | +8.1% | 0.01% | +100.0% |
Q3 2013 | $65,854,000 | +43.2% | 1,227,260 | +18.4% | 0.01% | +20.0% |
Q2 2013 | $45,985,000 | – | 1,036,387 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
TOBAM | 318,384 | $23,994,000 | 0.94% |
Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |